. "Prognostick\u00FD v\u00FDznam a praktick\u00E9 vyu\u017Eit\u00ED s\u00E9riov\u00E9 kvantitativn\u00ED detekce marker\u016F v mo\u010Di u pacient\u016F s povrchov\u00FDmi uroteli\u00E1ln\u00EDmi karcinomy mo\u010Dov\u00E9ho m\u011Bch\u00FD\u0159e" . "carcinoma of urinary bladder" . "0"^^ . . "1"^^ . . " serial marker samples" . . . "0"^^ . . " recurrence of carcinoma" . . . "carcinoma of urinary bladder; noninvasive detection; serial marker samples; BLCA-4; BTA TRAK; UBC IRMA; recurrence of carcinoma; cystoscopy check"@en . "Urin.cyt.is the best adjunctive met.to cystoscopy in pat.with Ta T1 bladder tumors bec. of its high sensit. in Tis,high spec. BTA TRAK better diag. char. than UBC IRMA. Using the low cut-of value-can help 1/3 pat. to postpone cystoscopy."@en . . "Prognostic value and practical application of serial quantitative detection of urine tumor markers in superficial urothelial urinary bladder carcinoma."@en . "http://www.isvav.cz/projectDetail.do?rowId=NR8095"^^ . "Cytolog. vy\u0161et\u0159en\u00ED mo\u010Di z\u016Fst\u00E1v\u00E1 pro vys.sezitivitu u Tis a spec.ide\u00E1ln\u00ED dop. met. k cystoskopii sledov\u00E1n\u00ED pac. s Ta a T1 n\u00E1dory m\u011Bch\u00FD\u0159e. Test BTA TRAK dosahuje lep\u0161\u00EDch diag. charak. ne\u017E UBC IRMA. P\u0159i n\u00EDzk\u00E9 prah.hodnot\u011B odd.cystoskopii a\u017E 1/3 pac."@cs . . "2007-08-08+02:00"^^ . "Za\u0159azeni budou pacienti s povrchov\u00FDm uroteli\u00E1ln\u00EDm karcinomem mo\u010Dov\u00E9ho m\u011Bch\u00FD\u0159e p\u0159ed TUR. P\u0159edm\u011Btem bude hodnocen\u00ED kvantitativn\u00EDch neinvazivn\u00EDch mo\u010Dov\u00FDch test\u016F. Budou provedeny p\u0159ed TUR, 2 t\u00FDdny po v\u00FDkonu a p\u0159ed ka\u017Edou kontroln\u00ED cystoskopi\u00ED. V \u010CR budou prov\u00E1d\u011Bny testy BTA TRAK a UBC IRMA. Perspektivn\u00ED test BLCA-4 bude realizov\u00E1n v USA. Seriov\u00E9 odb\u011Bry marker\u016F umo\u017En\u00ED korelovat jejich dynamiku s pr\u016Fb\u011Bhem onemocn\u011Bn\u00ED, tedy vznikem recidivy nebo progrese. Hodnocena a srovn\u00E1v\u00E1na bude senzitivita test\u016F p\u0159i z\u00E1chytu prim\u00E1rn\u00EDho tumoru a recidiv. Posuzov\u00E1na bude dynamika zm\u011Bn hodnot marker\u016F po TUR a b\u011Bhem sledov\u00E1n\u00ED, co\u017E umo\u017En\u00ED navrhnout metodiku stanoven\u00ED individu\u00E1ln\u00ED prahov\u00E9 hodnoty. Studie p\u0159inese n\u00E1vrh pou\u017Eit\u00ED marker\u016F p\u0159i sledov\u00E1n\u00ED pacient\u016F s anamn\u00E9zou povrchov\u00FDch n\u00E1dor\u016F m\u011Bch\u00FD\u0159e. Umo\u017En\u00ED sn\u00ED\u017Eit po\u010Det cystoskopick\u00FDch kontrol, co\u017E bude m\u00EDt p\u0159\u00EDnos pro kvalitu pacientova \u017Eivota i ekonomick\u00FD." . " UBC IRMA" . . . " noninvasive detection" . . . . . . . "NR8095" . . . " BLCA-4" . "Patients with superficial bladder carcinoma before TUR will be included into the project. The subject of the project will be accessing of quantitative noninvasive urinary tests before TUR, two weeks after the operation and before every cystoscopy checks. BTA TRAK and UBC IRMA tests will be carried out in the Czech Rep. A perspectiove test BLCA-4 will be carried out in the USA. Serial sample taking of the markers will enable to correlate their dynamics with the disease development. The test sensitivity when detecting the primary tumor and recurrence will be accessed and compared. The dynamics of the markers after TUR and during the surveillance will be accessed, which will enable to suggest and individual threshold value. The project will bring a proposal of how to use markers during the surveillance of the patients with superficial bladder carcinoma. It will enable to reduce the number of cystoscopy checks, which will improve the quality of patients life."@en . " BTA TRAK" . "7"^^ . "7"^^ .